These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7938135)

  • 1. Ontogeny of biphasic locomotor effects of quinpirole.
    Van Hartesveldt C; Meyer ME; Potter TJ
    Pharmacol Biochem Behav; 1994 Jul; 48(3):781-6. PubMed ID: 7938135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulpiride antagonizes the biphasic locomotor effects of quinpirole in weanling rats.
    Frantz KJ; Van Hartesveldt C
    Psychopharmacology (Berl); 1995 Jun; 119(3):299-304. PubMed ID: 7675965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction.
    Garrett BE; Holtzman SG
    Eur J Pharmacol; 1994 Sep; 262(1-2):65-75. PubMed ID: 7813580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.
    Svensson K; Carlsson A; Huff RM; Kling-Petersen T; Waters N
    Eur J Pharmacol; 1994 Oct; 263(3):235-43. PubMed ID: 7843260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The locomotor effects of a putative dopamine D3 receptor agonist in developing rats.
    Frantz K; Babcock D; Van Hartesveldt C
    Eur J Pharmacol; 1996 Apr; 302(1-3):1-6. PubMed ID: 8790984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal and environmental effects on quinpirole-induced biphasic locomotion in rats.
    Van Hartesveldt C
    Pharmacol Biochem Behav; 1997 Dec; 58(4):955-60. PubMed ID: 9408200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-channel blockers attenuate the presynaptic effects of the D2/D3 agonist quinpirole in monkeys.
    Rosenzweig-Lipson S; Barrett JE
    Pharmacol Biochem Behav; 1995 Aug; 51(4):843-8. PubMed ID: 7675867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole.
    Beerepoot P; Lam V; Luu A; Tsoi B; Siebert D; Szechtman H
    Neurosci Lett; 2008 Dec; 446(2-3):101-4. PubMed ID: 18824069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze.
    Vorhees CV; Johnson HL; Burns LN; Williams MT
    Neurotoxicol Teratol; 2009; 31(1):1-10. PubMed ID: 18930132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice.
    Cook CD; Newman JL; Winfree JC; Beardsley PM
    Pharmacol Biochem Behav; 2004 Feb; 77(2):309-18. PubMed ID: 14751459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clorgyline-induced switch from locomotion to mouthing in sensitization to the dopamine D2/D3 agonist quinpirole in rats: role of sigma and imidazoline I2 receptors.
    Culver KE; Szechtman H
    Psychopharmacology (Berl); 2003 May; 167(2):211-8. PubMed ID: 12652347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats.
    Kurashima M; Yamada K; Nagashima M; Shirakawa K; Furukawa T
    Pharmacol Biochem Behav; 1995 Nov; 52(3):503-8. PubMed ID: 8545466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The locomotor effects of quinpirole in rats depend on age and gender.
    Frantz KJ; Van Hartesveldt C
    Pharmacol Biochem Behav; 1999 Dec; 64(4):821-6. PubMed ID: 10593206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre- and postsynaptic mechanisms.
    Perreault ML; Graham D; Bisnaire L; Simms J; Hayton S; Szechtman H
    Neuropsychopharmacology; 2006 Sep; 31(9):1967-81. PubMed ID: 16237381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole.
    Szechtman H; Dai H; Mustafa S; Einat H; Sullivan RM
    Pharmacol Biochem Behav; 1994 Aug; 48(4):921-8. PubMed ID: 7972297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D1/D2 agonists injected into nucleus accumbens and ventral pallidum differentially affect locomotor activity depending on site.
    Gong W; Neill DB; Lynn M; Justice JB
    Neuroscience; 1999; 93(4):1349-58. PubMed ID: 10501459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in behavioral sensitivity to SKF-38393 and quinpirole following withdrawal from continuous cocaine administration in rats.
    Neisewander JL; Lucki I; McGonigle P
    Pharmacol Biochem Behav; 1996 Apr; 53(4):935-42. PubMed ID: 8801600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.
    Graham DL; Hoppenot R; Hendryx A; Self DW
    Psychopharmacology (Berl); 2007 Apr; 191(3):719-30. PubMed ID: 16835769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated quinpirole treatment: locomotor activity, dopamine synthesis, and effects of selective dopamine antagonists.
    Rowlett JK; Mattingly BA; Bardo MT
    Synapse; 1995 Jul; 20(3):209-16. PubMed ID: 7570352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole.
    Zhou LW; Qin ZH; Weiss B
    Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.